Dulaglutide: difference between revisions
Diff·revision 10 → 11·17:45, 9 Mar 2025
Difference between revision 10 and revision 11 of Dulaglutide. 2 lines changed; the page grew by 171 bytes.
| Revision 10 — 22:43, 10 Feb 2025 SVG_Solomon (talk) add see also to the amylin analogue 3,990 bytes ±0 | Revision 11 — 17:45, 9 Mar 2025 MolarMassMaeve (talk) convert the substitution list to a table so the analogues line up 4,161 bytes +171 | ||
|---|---|---|---|
| 30 | The REWIND trial randomised 9,901 people with type 2 diabetes, most of whom did not have established cardiovascular disease, and reported a hazard ratio of 0.88 (95% CI 0.79–0.99) for the primary cardiovascular composite over a median 5.4 years. Its distinctive feature is the predominantly primary-prevention population, which differentiates it from the outcome trials of other agents in the class and makes its result harder to compare with them.{{r|gerstein2019}} | 30 | The REWIND trial randomised 9,901 people with type 2 diabetes, most of whom did not have established cardiovascular disease, and reported a hazard ratio of 0.88 (95% CI 0.79–0.99) for the primary cardiovascular composite over a median 5.4 years. Its distinctive feature is the predominantly primary-prevention population, which differentiates it from the outcome trials of other agents in the class and makes its result harder to compare with them.{{r|gerstein2019}} |
| 31 | 31 | ||
| + | 32 | Effect sizes for weight are modest relative to [[Semaglutide|semaglutide]] and [[Tirzepatide|tirzepatide]], and dulaglutide does not hold a weight-management indication. | |
| + | 33 | ||
| 32 | == References == | 34 | == References == |
| 33 | {{reflist}} | 35 | {{reflist}} |